Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Novobiocin Sodium
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Varsity Pharmaceuticals Licenses Pol-Theta Inhibitor
Details : VP-006 (Novobiocin), a drug previously used as an antibiotic, is a potent Pol-Theta enzyme inhibitor that can be used alone or in combination with PARP inhibitors to treat HR-deficient tumors, even after they have become resistant to PARP inhibitor thera...
Product Name : VP-006
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 02, 2022
Lead Product(s) : Novobiocin Sodium
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable